To date, mutations in MYD88 have been implicated in primary breast DLBCL [20], primary renal lymphoma [26], central nervous system DLBCL [27,28,34], and primary testicular lymphoma [33]. Here, MYD88 is linked to breast diffuse large B-cell lymphoma.